Effect of Dual Bronchodilation With Umeclidinium/Vilanterol on Patients With COPD, Hyperinflation and Heart Failure
NCT ID: NCT04522596
Last Updated: 2024-02-28
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE4
Total Enrollment
60 participants
Study Classification
INTERVENTIONAL
Study Start Date
2021-05-21
Study Completion Date
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Double-blind, randomized, two-period crossover, placebo-controlled, single-center study, to determine the effect of umeclidinium/vilanterol 55/22 μg compared with placebo on the increase in left systolic chamber function during exercise in patients with COPD, lung hyperinflation and mild to moderate left ventricular dysfunction.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cross-Over Study in Subjects With COPD, Evaluating Lung Function Response After Treatment With Once Daily Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg
NCT01716520
Pulmonary Disease, Chronic Obstructive
COMPLETED
PHASE3
A Study to Evaluate the Effect of the Combination of Umeclidinium (UMEC) and Vilanterol (VI) on Exercise Endurance Time (EET) in Participants With Chronic Obstructive Pulmonary Disease (COPD)
NCT02275052
Pulmonary Disease, Chronic Obstructive
COMPLETED
PHASE4
A Cross-Over Study to Evaluate Lung Function Response After Treatment With Umeclidinium (UMEC) 62.5 Micrograms (mcg), Vilanterol (VI) 25 mcg, and Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 mcg Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT02014480
Pulmonary Disease, Chronic Obstructive
COMPLETED
PHASE3
The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD
NCT01777334
Pulmonary Disease, Chronic Obstructive
COMPLETED
PHASE3
A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT01822899
Pulmonary Disease, Chronic Obstructive
COMPLETED
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Phase IV clinical trial, single-center, double-blind, randomized, two-period crossover, placebo-controlled, to determine the effect of treatment with umeclidinium/vilanterol 55/22 μg compared with placebo on the increase in left systolic chamber function during exercise in patients with COPD, lung hyperinflation and mild to moderate left ventricular dysfunction.
The participants will be patients from the outpatient offices of the Cardiology, Pulmonology and Internal Medicine departments of the Gregorio Marañon University Hospital in Madrid, over 40 years of age with a diagnosis of COPD, lung hyperinflation with a residual volume more than 135 % and stable heart failure with a left ventricular ejection fraction between 35-55%.
Patients will be randomly assigned (1:1) to either umeclidinium/vilanterol 55/22 μg Ellipta for 14 days followed by a washout period of 14 days and then placebo for 14 days, or the same treatments in reverse order.
The randomization numbers will be generated by blocks of 4 elements selected with a computer-generated random list.
Patients, investigators, individuals in charge of the assessments, sponsor, CRO staff, and data analysts will be blinded to the identity and assignment of the treatments from the time of randomization until database lock, using the following methods:
1. Randomization data will be kept confidential until the time of unmasking (unlocking the database) and will not be accessible to anyone else involved in the study and
2. The identities of the treatments will be concealed by the use of active drugs and placebo identical in packaging, labeling, schedule of administration, appearance, and taste.
Two crossover treatment periods (treatments 1 and 2) of 14 days each separated by 14 days washout, and follow-up. The active treatment will be a combination of umeclidinium/vilanterol 55/22 μg Ellipta given by inhalation once per day over 14 days. Matching placebo will be used as a control. Any ongoing hypertensive and cardiovascular medications (including beta-blockers if prescribed) will be kept stable throughout the study. All previous COPD medications except inhaled corticosteroids (if dose stable for at least 30 days) will be withdrawn. Patients will be given salbutamol as rescue medication throughout the study and the respective study drugs in the treatment phases.
All adverse effects (AEs) spontaneously referred to either by the patients or during the visits will be registered and notified. All AEs will be collected, including those that are not considered associated with the study treatment.
All clinical information will be anonymously recorded in an e-CRF system programmed using in-house resources.
Any abnormal result of the study variables that the investigator considers clinically significant and require adjustments or transient or permanent interruption of treatment or any type of intervention or diagnostic evaluation to assess the associated risk for the patient will be collected as an adverse event and should be investigated and monitored adequately.
During the study, cardiac parameters will be determined by exercise echocardiography and MRI and assessed by experienced cardiologists (with cardiac MRI experience) blinded to all clinical and trial-related data.
Lung function will be assessed using constant-volume body plethysmography and spirometry in accordance with the American Thoracic Society and European Respiratory Society standards.
Patients will undergo a symptom-limited bicycle-exercise test at 30⁰ lateral decubitus in a dedicated ergometer (Easystress, Ecogito Medical SPRL, Liege, Belgium). Workrate will be initiated at 25 W and increased by 15 W every 3 min. The gas exchange will be simultaneously analyzed breath-by-breath (Ergostik, Geratherm, Germany). Doppler-derived stroke volume, systolic ejection period, and left ventricular outflow tract, at a specific point from the aortic valve, will be measured as recommended. The LV outflow tract cross-sectional area will be assumed constant so that the change in SV will be determined by the change in the outflow tract time-velocity integral as measured by pulsed-wave Doppler. We have recently validated the Doppler-derived method for measuring SV during exercise.
Baseline LV volumes and ejection fraction will be measured using the biplane Simpson's method. In addition, color-Doppler M-mode images will be acquired at baseline and during all exercise phases both for the ejection and diastolic phases at the outflow and inflow tract locations, respectively. These recordings have been validated both in clinical and preclinical studies as robust and load-independent indices of global LV systolic chamber function and diastolic suction, respectively. Furthermore, the ejection intraventricular pressure difference (EIVPD) is a simple but very sensitive method to detect subtle changes in LV systolic function, undetectable by other conventional methods.
Because frequently patients do not reach the anaerobic threshold during exercise echocardiography (decubitus…), a separate maximal ergospirometry on a cycle ergometer will be performed to measure peak exercise capacity. The cycle ergometer (ER-900, Vyasis, Hochberg, Germany) exercise test will start with a period of quiet breathing for at least 3 min followed by unloaded pedaling for 3 min, thereafter an immediate increase in work rate to 10 W and then by further increments of 10 W every minute until symptom limitation during which breath by breath gas exchange ( i.e. VO2 and VCO2) (Oxycon-pro Vyasis, Hoechberg Germany) lactate threshold (if attained by the patient) maximum ventilation and heart-rate dyspnea, inspiratory capacity and exercise flow-volume loops (every 2 min) and HR recovery rate will be measured. Peak oxygen uptake will be defined as the greatest work rate that was maintained for ≥30 s at 50-70 rpm.
Patients will undergo a conventional cardiac MRI study (Philips Achieva 1.5 T) without gadolinium to assess the size of the left and right ventricles. In addition, phase-contrast studies will be obtained to address cardiac output and flow characteristics at the level of the aorta and the main pulmonary artery, as previously described.
Patient reported outcomes will be assessed using the COPD assessment test (CAT) to measure health status and the transition dyspnea index to measure dyspnea.
External data monitorization and Adverse Event Reporting shall be contracted to an independent CRO, following current standards of clinical investigation
Primary objective:
To address the effect (compared with placebo) of umeclidinium/vilanterol 55/22 μg on the increase in exercise stroke volume (from baseline).
Secondary objectives:
To address the effect (compared with placebo) of umeclidinium/vilanterol 55/22 μg on the reduction of dynamic hyperinflation (from baseline).
To address the effect (compared with placebo) of umeclidinium/vilanterol 55/22 μg on resting cardiac function (from baseline).
To address the effect (compared with placebo) of umeclidinium/vilanterol 55/22 μg on PROMs (patient-reported outcomes measurement) from baseline.
The participants will be patients from the outpatient offices of the Cardiology, Pulmonology and Internal Medicine departments of the Gregorio Marañon University Hospital in Madrid, over 40 years of age with a diagnosis of COPD, lung hyperinflation with a residual volume more than 135 % and stable heart failure with a left ventricular ejection fraction between 35-55%.
Patients will be randomly assigned (1:1) to either umeclidinium/vilanterol 55/22 μg Ellipta for 14 days followed by a washout period of 14 days and then placebo for 14 days, or the same treatments in reverse order.
The randomization numbers will be generated by blocks of 4 elements selected with a computer-generated random list.
Patients, investigators, individuals in charge of the assessments, sponsor, CRO staff, and data analysts will be blinded to the identity and assignment of the treatments from the time of randomization until database lock, using the following methods:
1. Randomization data will be kept confidential until the time of unmasking (unlocking the database) and will not be accessible to anyone else involved in the study and
2. The identities of the treatments will be concealed by the use of active drugs and placebo identical in packaging, labeling, schedule of administration, appearance, and taste.
Two crossover treatment periods (treatments 1 and 2) of 14 days each separated by 14 days washout, and follow-up. The active treatment will be a combination of umeclidinium/vilanterol 55/22 μg Ellipta given by inhalation once per day over 14 days. Matching placebo will be used as a control. Any ongoing hypertensive and cardiovascular medications (including beta-blockers if prescribed) will be kept stable throughout the study. All previous COPD medications except inhaled corticosteroids (if dose stable for at least 30 days) will be withdrawn. Patients will be given salbutamol as rescue medication throughout the study and the respective study drugs in the treatment phases.
All adverse effects (AEs) spontaneously referred to either by the patients or during the visits will be registered and notified. All AEs will be collected, including those that are not considered associated with the study treatment.
All clinical information will be anonymously recorded in an e-CRF system programmed using in-house resources.
Any abnormal result of the study variables that the investigator considers clinically significant and require adjustments or transient or permanent interruption of treatment or any type of intervention or diagnostic evaluation to assess the associated risk for the patient will be collected as an adverse event and should be investigated and monitored adequately.
During the study, cardiac parameters will be determined by exercise echocardiography and MRI and assessed by experienced cardiologists (with cardiac MRI experience) blinded to all clinical and trial-related data.
Lung function will be assessed using constant-volume body plethysmography and spirometry in accordance with the American Thoracic Society and European Respiratory Society standards.
Patients will undergo a symptom-limited bicycle-exercise test at 30⁰ lateral decubitus in a dedicated ergometer (Easystress, Ecogito Medical SPRL, Liege, Belgium). Workrate will be initiated at 25 W and increased by 15 W every 3 min. The gas exchange will be simultaneously analyzed breath-by-breath (Ergostik, Geratherm, Germany). Doppler-derived stroke volume, systolic ejection period, and left ventricular outflow tract, at a specific point from the aortic valve, will be measured as recommended. The LV outflow tract cross-sectional area will be assumed constant so that the change in SV will be determined by the change in the outflow tract time-velocity integral as measured by pulsed-wave Doppler. We have recently validated the Doppler-derived method for measuring SV during exercise.
Baseline LV volumes and ejection fraction will be measured using the biplane Simpson's method. In addition, color-Doppler M-mode images will be acquired at baseline and during all exercise phases both for the ejection and diastolic phases at the outflow and inflow tract locations, respectively. These recordings have been validated both in clinical and preclinical studies as robust and load-independent indices of global LV systolic chamber function and diastolic suction, respectively. Furthermore, the ejection intraventricular pressure difference (EIVPD) is a simple but very sensitive method to detect subtle changes in LV systolic function, undetectable by other conventional methods.
Because frequently patients do not reach the anaerobic threshold during exercise echocardiography (decubitus…), a separate maximal ergospirometry on a cycle ergometer will be performed to measure peak exercise capacity. The cycle ergometer (ER-900, Vyasis, Hochberg, Germany) exercise test will start with a period of quiet breathing for at least 3 min followed by unloaded pedaling for 3 min, thereafter an immediate increase in work rate to 10 W and then by further increments of 10 W every minute until symptom limitation during which breath by breath gas exchange ( i.e. VO2 and VCO2) (Oxycon-pro Vyasis, Hoechberg Germany) lactate threshold (if attained by the patient) maximum ventilation and heart-rate dyspnea, inspiratory capacity and exercise flow-volume loops (every 2 min) and HR recovery rate will be measured. Peak oxygen uptake will be defined as the greatest work rate that was maintained for ≥30 s at 50-70 rpm.
Patients will undergo a conventional cardiac MRI study (Philips Achieva 1.5 T) without gadolinium to assess the size of the left and right ventricles. In addition, phase-contrast studies will be obtained to address cardiac output and flow characteristics at the level of the aorta and the main pulmonary artery, as previously described.
Patient reported outcomes will be assessed using the COPD assessment test (CAT) to measure health status and the transition dyspnea index to measure dyspnea.
External data monitorization and Adverse Event Reporting shall be contracted to an independent CRO, following current standards of clinical investigation
Primary objective:
To address the effect (compared with placebo) of umeclidinium/vilanterol 55/22 μg on the increase in exercise stroke volume (from baseline).
Secondary objectives:
To address the effect (compared with placebo) of umeclidinium/vilanterol 55/22 μg on the reduction of dynamic hyperinflation (from baseline).
To address the effect (compared with placebo) of umeclidinium/vilanterol 55/22 μg on resting cardiac function (from baseline).
To address the effect (compared with placebo) of umeclidinium/vilanterol 55/22 μg on PROMs (patient-reported outcomes measurement) from baseline.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Copd
Heart Failure
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
CROSSOVER
Phase IV clinical trial, single-center, double-blind, randomized, two-period crossover, placebo-controlled.
Primary Study Purpose
TREATMENT
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Umeclidinium/vilanterol
Umeclidinium/vilanterol 55/22 μg inhaled once a day for 14 days.
Group Type
EXPERIMENTAL
Umeclidinium/vilanterol
Intervention Type
DRUG
Umeclidinium/vilanterol 55/22 μg inhaled once a day
Placebo
Placebo inhaled once a day for 14 days.
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
OTHER
Placebo inhaled once a day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Umeclidinium/vilanterol
Umeclidinium/vilanterol 55/22 μg inhaled once a day
Intervention Type
DRUG
Placebo
Placebo inhaled once a day
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age between 40 and 85 years with a clinical diagnosis of COPD
* Airflow limitation indicated by a screening post-bronchodilator FEV1 \< 80% and \>35% predicted and a post-bronchodilator FEV1/FVC \< 0.7
* Smoking history of at least ten pack-years
* Baseline lung hyperinflation with a residual volume of more than 135% predicted
* Stable heart failure
* Left ventricle ejection fraction in the range of 35% to 55%.
* A suitable ultrasonic window from the apical view
* No exacerbation within 2 months before study recruitment (defined as the use of systemic corticoids, antibiotics, or hospitalization)
* Airflow limitation indicated by a screening post-bronchodilator FEV1 \< 80% and \>35% predicted and a post-bronchodilator FEV1/FVC \< 0.7
* Smoking history of at least ten pack-years
* Baseline lung hyperinflation with a residual volume of more than 135% predicted
* Stable heart failure
* Left ventricle ejection fraction in the range of 35% to 55%.
* A suitable ultrasonic window from the apical view
* No exacerbation within 2 months before study recruitment (defined as the use of systemic corticoids, antibiotics, or hospitalization)
Exclusion Criteria
* Do not sign the informed consent
* Unstable cardiovascular diseases
* Atrial fibrillation or other arrhythmias requiring treatment
* Unstable ischemic heart disease
* Uncontrolled hypertension
* Patients unable to undergo cardiac MR scanning (claustrophobia or carrying non-MR-compatible devices)
* Patients unable to perform an exercise test (locomotor conditions)
* Unstable cardiovascular diseases
* Atrial fibrillation or other arrhythmias requiring treatment
* Unstable ischemic heart disease
* Uncontrolled hypertension
* Patients unable to undergo cardiac MR scanning (claustrophobia or carrying non-MR-compatible devices)
* Patients unable to perform an exercise test (locomotor conditions)
Minimum Eligible Age
40 Years
Maximum Eligible Age
85 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Luis Puente Maestu
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Luis Puente Maestu
Professor
Responsibility Role
SPONSOR_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Luis Puente-Maestu, Prof
Role: STUDY_DIRECTOR
Instituto de Investigación Sanitaria Gregorio Mrañón
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital General Universitario Gregorio Marañón
Madrid, , Spain
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Spain
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2019-004427-20
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
CHHEF
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT01879410
COMPLETED
PHASE3
A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT01817764
COMPLETED
PHASE3
An Efficacy Study of Umeclidinium/Vilanterol With Tiotropium/Olodaterol in COPD Patients
NCT02799784
COMPLETED
PHASE4
A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium/Vilanterol (UMEC/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT02152605
COMPLETED
PHASE3
Pharmacokinetics Of Umeclidinium and Vilanterol in Healthy Chinese, a Randomized, Open Label, 3 Crossover Study.
NCT01899638
COMPLETED
PHASE1
A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT03034915
COMPLETED
PHASE4
Comparative Study of Umeclidinium/Vilanterol (UMEC/VI) in a Fixed Dose Combination With Indacaterol Plus Tiotropium
NCT02257385
COMPLETED
PHASE3
Effect of the Inhaled Triple Therapies Over the Small Airway in Biomass Exposure
NCT06571942
RECRUITING
PHASE4
Effect of Indacaterol Maleate in Chronic Obstructive Pulmonary Disease (COPD) on Lung Volume and Related Dyspnea
NCT01377051
COMPLETED
PHASE4
Efficacy and Safety Study of QVA149 in COPD Patients
NCT02487446
COMPLETED
PHASE3
Comparative Study of Fluticasone Furoate(FF)/Umeclidinium Bromide (UMEC)/ Vilanterol (VI) Closed Therapy Versus FF/VI Plus UMEC Open Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT02729051
COMPLETED
PHASE3
Efficacy and Safety of ICS/LABA vs. LAMA/LABA in Patients With Different COPD Phenotypes.
NCT05342558
COMPLETED
PHASE4
Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.
NCT02487498
COMPLETED
PHASE3
Efficacy and Safety of Levalbuterol in Chronic Obstructive Pulmonary Disease (COPD)
NCT00665600
COMPLETED
PHASE3
Evaluate the Effects of Formoterol and Beclomethasone Dipropionate Combination Therapy on Small Airways Function
NCT01466712
UNKNOWN
PHASE4
Safety And Efficacy Of GSK233705 Plus Salmeterol Compared With 2 Active Comparators And Placebo In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT00422604
COMPLETED
PHASE2
Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2
NCT02119286
COMPLETED
PHASE3
Phase IV O2 Consumption Study in COPD Patients.
NCT02533505
COMPLETED
PHASE4
An Exploratory Study, to Assess the Effect of Repeat-dose Inhaled Indacaterol Maleate (300 μg) on Dynamic and Static Lung Hyperinflation, Subjective Breathlessness and Health Status in Patients With Chronic Obstructive Pulmonary Disease(COPD)
NCT00636961
COMPLETED
PHASE2
Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT01957163
COMPLETED
PHASE3
Efficacy and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT01119950
COMPLETED
PHASE2
Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators
NCT07133880
RECRUITING
PHASE4
A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPD
NCT01313650
COMPLETED
PHASE3